Abstract
No public abstract is available from the verified source records.
Roger S. McIntyre, Christian S. Hendershot, Elisabet Jerlhag, Anders Fink-Jensen
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
From the discovery of GLP-1 to today’s diabetes/obesity therapy and beyond
10.1016/j.biopsych.2026.04.010 · 2026
GLP-1 and alcohol-related behaviors: Insights from preclinical studies
10.1016/j.biopsych.2026.04.022 · 2026
Glucagon-like peptide-1 receptor agonists as a candidate treatment for opioid use disorder: From rats to humans
10.1016/j.biopsych.2026.06.033 · 2026
GLP-1 receptor agonist medications: Interactions with addiction neurocircuitry
10.1016/j.biopsych.2026.01.011 · 2026
Glucagon-like peptide-1 receptor agonists in psychiatry: A pharmacoepidemiological scoping review
10.1016/j.biopsych.2026.03.1002 · 2026
From satiety to substance use: Neural mechanisms of Glucagon-like peptide-1 signaling in appetite and reward
10.1016/j.biopsych.2026.06.015 · 2026
Glucagon-like peptide-1 signaling in learning and memory: Evidence, mechanisms, and therapeutic implications
10.1016/j.biopsych.2026.06.006 · 2026
Preclinical and emerging clinical evidence supporting the translational potential of GLP-1 receptor agonists for treating psychostimulant and nicotine use disorders
10.1016/j.biopsych.2026.05.002 · 2026
Therapeutic potential of incretin-based therapies for alcohol use disorder: A narrative review of available clinical evidence
10.1016/j.biopsych.2026.07.010 · 2026
Therapeutic potential of glucagon-like peptide-1 receptor agonists for smoking cessation
10.1016/j.biopsych.2026.04.002 · 2026
Glucagon-like peptide-1 receptor agonists for mood disorders and suicide risk
10.1016/j.biopsych.2026.04.019 · 2026
The expanding landscape of GLP-1 medicines
10.1038/s41591-025-04124-5 · 2026
Muscle atrophy associated with glucagon-like peptide-1 receptor agonists: A population-based observational study
10.1016/j.clnu.2026.106620 · 2026
Updated trends in the global prevalence and burden of mental disorders, 1990-2023: A systematic analysis for the Global Burden of Disease Study 2023
10.1016/s0140-6736(26)00519-2 · 2026
Global, regional, and national trends in the morbidity gap and contributing diseases, injuries, and risk factors, 1990-2023: A systematic analysis for the Global Burden of Disease Study 2023
10.1016/s2468-2667(26)00098-8 · 2026
Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial
10.1001/jamapsychiatry.2024.4789 · 2025
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(26)00305-3 · 2026
Once-weekly semaglutide in adults with daily cigarette use: A randomized clinical trial
10.1001/jamanetworkopen.2026.14898 · 2026
Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov
2026
Semaglutide and effort-based decision-making in major depressive disorder: A randomized clinical trial
10.1001/jamapsychiatry.2026.0594 · 2026
Prescribing GLP-1 receptor agonists for persons with mental disorders: Evidence-based and aspirational targets
10.4088/jcp.26com16484 · 2026
No additional external references are available.